621 related articles for article (PubMed ID: 23103855)
1. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
[TBL] [Abstract][Full Text] [Related]
2. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
[TBL] [Abstract][Full Text] [Related]
3. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Henneman L; van Miltenburg MH; Michalak EM; Braumuller TM; Jaspers JE; Drenth AP; de Korte-Grimmerink R; Gogola E; Szuhai K; Schlicker A; Bin Ali R; Pritchard C; Huijbers IJ; Berns A; Rottenberg S; Jonkers J
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8409-14. PubMed ID: 26100884
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
5. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Zander SA; Kersbergen A; van der Burg E; de Water N; van Tellingen O; Gunnarsdottir S; Jaspers JE; Pajic M; Nygren AO; Jonkers J; Borst P; Rottenberg S
Cancer Res; 2010 Feb; 70(4):1700-10. PubMed ID: 20145144
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
Barazas M; Gasparini A; Huang Y; Küçükosmanoğlu A; Annunziato S; Bouwman P; Sol W; Kersbergen A; Proost N; de Korte-Grimmerink R; van de Ven M; Jonkers J; Borst GR; Rottenberg S
Cancer Res; 2019 Feb; 79(3):452-460. PubMed ID: 30530501
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Nacson J; Krais JJ; Bernhardy AJ; Clausen E; Feng W; Wang Y; Nicolas E; Cai KQ; Tricarico R; Hua X; DiMarcantonio D; Martinez E; Zong D; Handorf EA; Bellacosa A; Testa JR; Nussenzweig A; Gupta GP; Sykes SM; Johnson N
Cell Rep; 2018 Sep; 24(13):3513-3527.e7. PubMed ID: 30257212
[TBL] [Abstract][Full Text] [Related]
9. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
To C; Kim EH; Royce DB; Williams CR; Collins RM; Risingsong R; Sporn MB; Liby KT
Cancer Prev Res (Phila); 2014 Jul; 7(7):698-707. PubMed ID: 24817481
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
11. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to PARP inhibitors--three and counting.
Fojo T; Bates S
Cancer Discov; 2013 Jan; 3(1):20-3. PubMed ID: 23319766
[TBL] [Abstract][Full Text] [Related]
13. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
15. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
17. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
18. The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Oplustil O'Connor L; Rulten SL; Cranston AN; Odedra R; Brown H; Jaspers JE; Jones L; Knights C; Evers B; Ting A; Bradbury RH; Pajic M; Rottenberg S; Jonkers J; Rudge D; Martin NM; Caldecott KW; Lau A; O'Connor MJ
Cancer Res; 2016 Oct; 76(20):6084-6094. PubMed ID: 27550455
[TBL] [Abstract][Full Text] [Related]
19. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
Bhin J; Paes Dias M; Gogola E; Rolfs F; Piersma SR; de Bruijn R; de Ruiter JR; van den Broek B; Duarte AA; Sol W; van der Heijden I; Andronikou C; Kaiponen TS; Bakker L; Lieftink C; Morris B; Beijersbergen RL; van de Ven M; Jimenez CR; Wessels LFA; Rottenberg S; Jonkers J
Cell Rep; 2023 May; 42(5):112538. PubMed ID: 37209095
[TBL] [Abstract][Full Text] [Related]
20. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
